NCT02991898 · OUTCOME

Number of Participants With Immune Reconstitution

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies · Source last updated 2020-09-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Assessed at Day 4, weekly for 8 weeks

What was measured

The proportion of patients with immune reconstitution. Continuous endpoints will be described by medians, ranges and interquartile ranges as well as means and standard deviations if normally distributed.

Analysis population: Samples were not analyzed, and so data not available for reporting.

Groups in this outcome

Treg Infusion

The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treg Infusion	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

description

groups

description
The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion
id
OG000
title
Treg Infusion

population Description

Samples were not analyzed, and so data not available for reporting.

reporting Status

POSTED

time Frame

Assessed at Day 4, weekly for 8 weeks

title

Number of Participants With Immune Reconstitution

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice